middle.news
Immutep Surpasses Enrollment Milestone in Pivotal Lung Cancer Trial
8:44am on Thursday 9th of October, 2025 AEDT
•
Healthcare
Read Story
Immutep Surpasses Enrollment Milestone in Pivotal Lung Cancer Trial
8:44am on Thursday 9th of October, 2025 AEDT
Key Points
TACTI-004 Phase III trial exceeds 170 patient enrollment
Over 100 clinical sites activated across 24 countries
Futility analysis scheduled for first quarter of 2026
Eftilagimod alfa combined with KEYTRUDA and chemotherapy
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE